EMBECTA CORP. Operating Expenses
EMBECTA CORP. (EMBC) reported Operating Expenses of $104.60 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-07
- EMBECTA CORP. operating expenses for the quarter ending 2026-06-30 was $104.60M, a 1.45% increase year-over-year.
- EMBECTA CORP. operating expenses for the quarter ending 2026-03-31 was $92.80M, a 8.30% decline year-over-year.
- EMBECTA CORP. operating expenses for the quarter ending 2025-12-31 was $78.40M, a 38.94% decline year-over-year.
- EMBECTA CORP. operating expenses for the quarter ending 2025-09-30 was $102.00M, a 30.89% decline year-over-year.
- EMBECTA CORP. operating expenses for fiscal 2025 was $434.70M, a 23.52% decline from fiscal 2024.
- EMBECTA CORP. operating expenses for fiscal 2024 was $568.40M, a 7.57% increase from fiscal 2023.
- EMBECTA CORP. operating expenses for fiscal 2023 was $528.40M, a 13.56% increase from fiscal 2022.
- EMBECTA CORP. operating expenses for fiscal 2022 was $465.30M, a 50.88% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $104.60M 10-Q · filed 2026-08-07 | $197.40M derived: sum of 2 quarters · filed 2026-08-07 | $275.80M 10-Q · filed 2026-08-07 | $377.80M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $92.80M 10-Q · filed 2026-05-05 | $171.20M 10-Q · filed 2026-05-05 | $273.20M derived: sum of 3 quarters · filed 2026-05-05 | $376.30M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $78.40M 10-Q · filed 2026-02-05 | $180.40M derived: sum of 2 quarters · filed 2026-02-05 | $283.50M derived: sum of 3 quarters · filed 2026-08-07 | $384.70M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-09-30 | $102.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $205.10M derived: sum of 2 quarters · filed 2026-08-07 | $306.30M derived: sum of 3 quarters · filed 2026-08-07 | $434.70M 10-K · filed 2025-11-25 |
| 2025-06-30 | $103.10M 10-Q · filed 2026-08-07 | $204.30M derived: sum of 2 quarters · filed 2026-08-07 | $332.70M 10-Q · filed 2026-08-07 | $480.30M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $101.20M 10-Q · filed 2026-05-05 | $229.60M 10-Q · filed 2026-05-05 | $377.20M derived: sum of 3 quarters · filed 2026-05-05 | $511.40M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $128.40M 10-Q · filed 2026-02-05 | $276.00M derived: sum of 2 quarters · filed 2026-02-05 | $410.20M derived: sum of 3 quarters · filed 2026-02-05 | $556.40M derived: sum of 4 quarters · filed 2026-02-05 |
| 2024-09-30 | $147.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $281.80M derived: sum of 2 quarters · filed 2025-11-25 | $428.00M derived: sum of 3 quarters · filed 2025-11-25 | $568.40M 10-K · filed 2025-11-25 |
| 2024-06-30 | $134.20M 10-Q · filed 2025-08-08 | $280.40M derived: sum of 2 quarters · filed 2025-08-08 | $420.80M 10-Q · filed 2025-08-08 | $576.80M derived: sum of 4 quarters · filed 2025-11-25 |
| 2024-03-31 | $146.20M 10-Q · filed 2025-05-09 | $286.60M 10-Q · filed 2025-05-09 | $442.60M derived: sum of 3 quarters · filed 2025-11-25 | $580.80M derived: sum of 4 quarters · filed 2025-11-25 |
| 2023-12-31 | $140.40M 10-Q · filed 2025-02-06 | $296.40M derived: sum of 2 quarters · filed 2025-11-25 | $434.60M derived: sum of 3 quarters · filed 2025-11-25 | $568.80M derived: sum of 4 quarters · filed 2025-11-25 |
| 2023-09-30 | $156.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $294.20M derived: sum of 2 quarters · filed 2025-11-25 | $428.40M derived: sum of 3 quarters · filed 2025-11-25 | $528.40M 10-K · filed 2025-11-25 |
| 2023-06-30 | $138.20M 10-Q · filed 2024-08-09 | $272.40M derived: sum of 2 quarters · filed 2024-08-09 | $372.40M 10-Q · filed 2024-08-09 | $552.30M derived: sum of 4 quarters · filed 2024-12-11 |
| 2023-03-31 | $134.20M 10-Q · filed 2024-05-09 | $234.20M 10-Q · filed 2024-05-09 | $414.10M derived: sum of 3 quarters · filed 2024-12-11 | $519.90M derived: sum of 4 quarters · filed 2024-12-11 |
| 2022-12-31 | $100.00M 10-Q · filed 2024-02-09 | $279.90M derived: sum of 2 quarters · filed 2024-12-11 | $385.70M derived: sum of 3 quarters · filed 2024-12-11 | $478.00M derived: sum of 4 quarters · filed 2024-12-11 |
| 2022-09-30 | $179.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-11 | $285.70M derived: sum of 2 quarters · filed 2024-12-11 | $378.00M derived: sum of 3 quarters · filed 2024-12-11 | $465.30M 10-K · filed 2024-12-11 |
| 2022-06-30 | $105.80M 10-Q · filed 2023-08-08 | $198.10M derived: sum of 2 quarters · filed 2023-08-08 | $285.40M 10-Q · filed 2023-08-08 | $378.40M derived: sum of 4 quarters · filed 2023-11-29 |
| 2022-03-31 | $92.30M 10-Q · filed 2023-05-12 | $179.60M 10-Q · filed 2023-05-12 | $272.60M derived: sum of 3 quarters · filed 2023-11-29 | $350.90M derived: sum of 4 quarters · filed 2023-11-29 |
| 2021-12-31 | $87.30M 10-Q · filed 2023-02-14 | $180.30M derived: sum of 2 quarters · filed 2023-11-29 | $258.60M derived: sum of 3 quarters · filed 2023-11-29 | $328.50M derived: sum of 4 quarters · filed 2023-11-29 |
| 2021-09-30 | $93.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-29 | $171.30M derived: sum of 2 quarters · filed 2023-11-29 | $241.20M derived: sum of 3 quarters · filed 2023-11-29 | $308.40M 10-K · filed 2023-11-29 |
| 2021-06-30 | $78.30M 10-Q · filed 2022-08-15 | $148.20M derived: sum of 2 quarters · filed 2022-08-15 | $215.40M 10-Q · filed 2022-08-15 | |
| 2021-03-31 | $69.90M 10-Q · filed 2022-05-13 | $137.10M 10-Q · filed 2022-05-13 | ||
| 2020-12-31 | $67.20M 10-Q · filed 2022-03-16 | |||
| 2020-09-30 | $276.10M 10-K · filed 2022-12-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |